Asia-Pacific Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Publish Reports
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 21
  • No of Figures: 109

Asia-Pacific Scleroderma Therapeutics Market By Type (Localized Scleroderma, Systemic Scleroderma), Treatment Type (Drug Treatment, Surgical Treatment, Therapy), End User (Hospital, Specialty Clinics, Homecare Settings, Others), Country (Japan, China, Australia, South Korea, India, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2026 – Industry Trends and Forecast to 2026

The scleroderma is an auto-immune disease of unknown etiology and is characterized by fibrosis and microvascular injury in affected organs. In this disease, Raynaud’s phenomenon is an initial symptom and shows puffiness of fingers. There are two types of scleroderma - localized scleroderma and limited cutaneous systemic sclerosis. Localized sclerosis shows plaques of fibrotic skin and subcutaneous tissue which further occurs as linear fibrotic bands on extremities such as skin and deeper tissue. Hence, it has two types in localized scleroderma and they are morphea and linear scleroderma. As per the studies carried out by researchers, it has been found that the disease occurs due to the changes in certain parameter in environment or changes in certain gene in human. The symptoms involves in this disease is abnormalities on the skin, painful joints, morning stiffness, fatigue, and/or weight loss and many others.

There is no drug or treatment available to treat scleroderma but there are certain drugs available which can be used in treating the disease associated to scleroderma such as kidney disease, Heartburn (acid reflux), Raynaud's phenomenon and others. Some of them are aspirin, naproxen, ibuprofen and many others.

Asia-Pacific scleroderma therapeutics market is projected to register a steady CAGR in the forecast period of 2019 to 2026.

Segmentation: Asia-Pacific Scleroderma Therapeutics Market

Asia-Pacific scleroderma therapeutics market is segmented into three notable segments such as type, treatment type, end user.

  • On the basis of type, the market is segmented into localized scleroderma and systemic scleroderma
    • In March 2019, Sanofi received FDA (Food and Drug Administration) approved Dupixent (dupilumab) which is useful for moderate-to-severe atopic dermatitis in adolescents. It is used for treating the skin related issues as it clears the skin and reduced itching in adolescents. With this approval the company has increased its portfolio and also increased its business bry provides product everywhere around the world.
  • On the basis of treatment type, the market is segmented into drug treatment, surgery treatment and therapy
    • In February 2018, Novartis's Sandoz division received U.S. approval for a larger dosage of its product called Glatopa drug which is useful for treatment of multiple sclerosis patients, approval of product reinforces company’s leadership in market.
  • On the basis of end user, the market is segmented into hospital, specialty clinics, homecare settings and others
    • In May 2017, F. Hoffmann-La Roche Ltd received U.S. Food and Drug Administration (FDA) for its product Actemra/RoActemra (tocilizumab) subcutaneous injection that is useful for treatment of GCA. GCA chronic and severe autoimmune condition and Actemra/RoActemra (tocilizumab) is the first FDA approved treatment for GCA in adults. It is the 6th approval after its first U.S. launch in 2010.

Competitive Analysis: Asia-Pacific Scleroderma Therapeutics Market

Some of the prominent participants operating in this market are Argentis Pharmaceuticals, LLC., F. Hoffmann-La Roche Ltd, AbbVie Inc., Pfizer Inc., Sanofi, ALLERGAN, viDA Therapeutics Inc., Novartis AG, Active Biotech AB., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., AstraZeneca, Daval International Limited and others.

Recent Developments:

  • In December 2018, GlaxoSmithKline plc acquired TESARO (U.S.) for approximately USD 5100.O million. This huge amount of transaction has significantly strengthened GSK’s pharmaceutical business by accelerating GSK’s pipeline and commercial capability in oncology.
  • In September 2017, AstraZeneca India set to expand its global medicines development group in Bengaluru. This helped in product and increase in late-stage and mature product portfolio. This has increased company’s strength in India where need for medicine is increasing.
  • In September 2015, Pfizer Inc. acquired Hospira, Inc. who is a global leader in biosimilar. With this acquisition Pfizer Inc. increased their product portfolio, employees and presence. The company has strengthened their position by providing broadest and most diverse portfolios in market.

Research Methodology: Asia-Pacific Scleroderma Therapeutics Market

Primary Respondents:

Key Opinion Leaders (KOL’s): Manufacturer, Healthcare Professionals, Doctors, Nurses, Medical practitioners.

Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and, National Sales Managers.


SKU-

TABLE OF CONTENTS ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY 1.2 MARKET DEFINITION 1.3 OVERVIEW OF ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET 1.4 CURRENCY AND PRICING 1.5 LIMITATIONS 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED 2.2 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET : GEOGRAPHICAL SCOPE 2.3 YEARS CONSIDERED FOR THE STUDY 2.4 CURRENCY AND PRICING 2.5 DBMR TRIPOD DATA VALIDATION MODEL 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.7 DBMR MARKET POSITION GRID 2.8 TIME LINE 2.9 MULTIVARIATE MODELLING 2.10 SECONDARY SOURCES 2.11 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 RISING CASES OF SCLERODERMA 3.1.2 INCREASING ACCESS TO MEDICAL INSURANCE IN THE U.S. 3.1.3 INCREASING MERGER AND ACQUISITIONS

3.2 RESTRAINTS

3.2.1 LACK OF CURATIVE TREATMENT 3.2.2 STRINGENT REGULATIONS 3.2.3 COUNTERFEIT PRODUCTS

3.3 OPPORTUNITY

3.3.1 UNMET PATIENT NEEDS IN SYSTEMIC SCLEROSIS

3.4 CHALLENGE

3.4.1 SIDE EFFECTS OF DRUGS

4 EXECUTIVE SUMMARY 5 PREMIUM INSIGHTS 6 PIPELINE PRODUCTS 7 EPIDEMIOLOGY

7.1 HISTORY OF SCLERODERMA: 7.2 RECENT INCIDENCE AND PREVALENCE: 7.3 CAUSE OF SCLERODERMA: 7.4 SYMPTOMS OF SCLERODERMA: 7.5 MANAGING SCLERODERMA:

8 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY TYPE

8.1 OVERVIEW 8.2 SYSTEMIC SCLERODERMA

8.2.1 LIMITED CUTANEOUS SYSTEMIC SCLEROSIS OR CREST SYNDROME 8.2.2 DIFFUSE SYSTEMIC SCLEROSIS

8.3 LOCALIZED SCLERODERMA

8.3.1 MORPHEA 8.3.2 LINEAR SCLERODERMA

9 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE

9.1 OVERVIEW 9.2 DRUG TREATMENT

9.2.1 DRUG TREATMENT, BY TYPE

9.2.1.1 ANTI-INFLAMMATORY DRUGS 9.2.1.2 IMMUNOSUPPRESSANTS 9.2.1.3 CORTICOSTEROIDS 9.2.1.4 PROTON PUMP INHIBITORS 9.2.1.5 CALCIUM CHANNEL BLOCKERS 9.2.1.6 ACE INHIBITORS 9.2.1.7 H2 BLOCKERS 9.2.1.8 PDE5 INHIBITORS 9.2.1.9 PROSTACYCLIN ANALOGUES 9.2.1.10 ENDOTHELIN RECEPTOR ANTAGONISTS 9.2.1.11 CHELATING AGENTS (EDATHAMIL DISODIUM) 9.2.1.12 OTHERS

9.2.2 DRUG TREATMENT, BY DISTRIBUTION CHANNEL

9.2.2.1 HOSPITAL PHARMACY 9.2.2.2 RETAIL PHARMACY 9.2.2.3 ONLINE PHARMACY 9.2.2.4 OTHERS

9.3 SURGICAL TREATMENT

9.4 THERAPY

9.4.1 ULTRAVIOLET LIGHT THERAPY 9.4.2 PHYSICAL THERAPY 9.4.3 OTHERS

10 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY END USER

10.1 OVERVIEW 10.2 HOSPITAL 10.3 SPECIALTY CLINICS 10.4 HOMECARE SETTINGS 10.5 OTHERS

11 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY GEOGRAPHY

11.1 ASIA-PACIFIC

11.1.1 JAPAN 11.1.2 CHINA 11.1.3 AUSTRALIA 11.1.4 SOUTH KOREA 11.1.5 INDIA 11.1.6 SINGAPORE 11.1.7 MALAYSIA 11.1.8 INDONESIA 11.1.9 THAILAND 11.1.10 PHILIPPINES 11.1.11 REST OF ASIA-PACIFIC

12 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

13 COMPANY PROFILES

13.1 ASTRAZENECA

13.1.1 COMPANY SNAPSHOT 13.1.2 REVENUE ANALYSIS 13.1.3 GEOGRAPHICAL PRESENCE 13.1.4 PRODUCT PORTFOLIO (PIPELINE) 13.1.5 RECENT DEVELOPMENTS

13.2 F. HOFFMANN-LA ROCHE LTD

13.2.1 COMPANY SNAPSHOT 13.2.2 REVENEUE ANALYSIS 13.2.3 GEOGRAPHICAL PRESENCE 13.2.4 PRODUCT PORTFOLIO 13.2.5 RECENT DEVELOPMENTS

13.3 NOVARTIS AG

13.3.1 COMPANY SNAPSHOT 13.3.2 REVENEUE ANALYSIS 13.3.3 GEOGRAPHICAL PRESENCE 13.3.4 PRODUCT PORTFOLIO 13.3.5 RECENT DEVELOPMENTS

13.4 PFIZER INC.

13.4.1 COMPANY SNAPSHOT 13.4.2 REVENEUE ANALYSIS 13.4.3 GEOGRAPHICAL PRESENCE 13.4.4 PRODUCT PORTFOLIO 13.4.5 RECENT DEVELOPMENTS

13.5 ABBVIE INC.

13.5.1 COMPANY SNAPSHOT 13.5.2 REVENEUE ANALYSIS 13.5.3 GEOGRAPHICAL PRESENCE 13.5.4 PRODUCT PORTFOLIO 13.5.5 RECENT DEVELOPMENTS

13.6 ACTIVE BIOTECH AB.

13.6.1 COMPANY OVERVIEW 13.6.2 REVENUE ANALYSIS 13.6.3 PRODUCT PORTFOLIO 13.6.4 RECENT DEVELOPMENT

13.7 ALLERGAN

13.7.1 COMPANY SNAPSHOT 13.7.2 REVENEUE ANALYSIS 13.7.3 GEOGRAPHICAL PRESENCE 13.7.4 PRODUCT PORTFOLIO 13.7.5 RECENT DEVELOPMENTS

13.8 ARGENTIS PHARMACEUTICALS, LLC.

13.8.1 COMPANY OVERVIEW 13.8.2 PRODUCT PORTFOLIO 13.8.3 RECENT DEVELOPMENTS

13.9 BRISTOL-MYERS SQUIBB COMPANY

13.9.1 COMPANY OVERVIEW 13.9.2 REVENUE ANALYSIS 13.9.3 GEOGRAPHICAL PRESENCE 13.9.4 PRODUCTS PORTFOLIO 13.9.5 RECENT DEVELOPMENTS

13.10 DAVAL INTERNATIONAL LIMITED

13.10.1 COMPANY SNAPSHOT 13.10.2 GEOGRAPHICAL PRESENCE 13.10.3 PRODUCT PORTFOLIO 13.10.4 RECENT DEVELOPMENT

13.11 GLAXOSMITHKLINE PLC.

13.11.1 COMPANY OVERVIEW 13.11.2 REVENUE ANALYSIS 13.11.3 GEOGRAPHICAL PRESENCE 13.11.4 PRODUCTS PORTFOLIO (PIPELINE DEVELOPMENT) 13.11.5 RECENT DEVELOPMENT

13.12 JOHNSON & JOHNSON SERVICES, INC.

13.12.1 COMPANY OVERVIEW 13.12.2 REVENUE ANALYSIS 13.12.3 GEOGRAPHICAL PRESENCE 13.12.4 PRODUCT PORTFOLIO (PIPELINE) 13.12.5 RECENT DEVELOPMENTS

13.13 SANOFI

13.13.1 COMPANY SNAPSHOT 13.13.2 REVENEUE ANALYSIS 13.13.3 GEOGRAPHICAL PRESENCE 13.13.4 PRODUCT PORTFOLIO 13.13.5 RECENT DEVELOPMENT

13.14 VIDA THERAPEUTICS INC.

13.14.1 COMPANY OVERVIEW 13.14.2 PRODUCT PORTFOLIO 13.14.3 RECENT DEVELOPMENTS

14 QUESTIONNAIRE 15 RELATED REPORTS

 

LIST OF TABLES ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET

TABLE 1 INSIGHTS ABOUT CLINICAL TRIAL PHASES OF VARIOUS DRUGS TABLE 2 INCIDENCE AND PREVALENCE IN PAST DECADE (REGION) TABLE 3 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 4 ASIA-PACIFIC SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION) TABLE 5 ASIA-PACIFIC SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 6 ASIA-PACIFIC LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION) TABLE 7 ASIA-PACIFIC LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 8 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 9 ASIA-PACIFIC DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 10 ASIA-PACIFIC DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 11 ASIA-PACIFIC DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 12 ASIA-PACIFIC SURGICAL TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION) TABLE 13 ASIA-PACIFIC THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 14 ASIA-PACIFIC THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 15 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 16 ASIA-PACIFIC HOSPITAL IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 17 ASIA-PACIFIC SPECIALTY CLINICS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 18 ASIA-PACIFIC HOMECARE SETTINGS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 19 ASIA-PACIFIC OTHERS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 20 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION) TABLE 21 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 22 ASIA-PACIFIC LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 23 ASIA-PACIFIC SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 24 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 25 ASIA-PACIFIC DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 26 ASIA-PACIFIC DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 27 ASIA-PACIFIC THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 28 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 29 JAPAN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 30 JAPAN LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 31 JAPAN SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 32 JAPAN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 33 JAPAN DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 34 JAPAN DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 35 JAPAN THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 36 JAPAN SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 37 CHINA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 38 CHINA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 39 CHINA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 40 CHINA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 41 CHINA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 42 CHINA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 43 CHINA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 44 CHINA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 45 AUSTRALIA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 46 AUSTRALIA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 47 AUSTRALIA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 48 AUSTRALIA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 49 AUSTRALIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 50 AUSTRALIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 51 AUSTRALIA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 52 AUSTRALIA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 53 SOUTH KOREA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 54 SOUTH KOREA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 55 SOUTH KOREA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 56 SOUTH KOREA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 57 SOUTH KOREA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 58 SOUTH KOREA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 59 SOUTH KOREA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 60 SOUTH KOREA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 61 INDIA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 62 INDIA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 63 INDIA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 64 INDIA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 65 INDIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 66 INDIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 67 INDIA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 68 INDIA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 69 SINGAPORE SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 70 SINGAPORE LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 71 SINGAPORE SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 72 SINGAPORE SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 73 SINGAPORE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 74 SINGAPORE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 75 SINGAPORE THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 76 SINGAPORE SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 77 MALAYSIA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 78 MALAYSIA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 79 MALAYSIA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 80 MALAYSIA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 81 MALAYSIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 82 MALAYSIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 83 MALAYSIA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 84 MALAYSIA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 85 INDONESIA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 86 INDONESIA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 87 INDONESIA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 88 INDONESIA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 89 INDONESIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 90 INDONESIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 91 INDONESIA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 92 INDONESIA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 93 THAILAND SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 94 THAILAND LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 95 THAILAND SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 96 THAILAND SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 97 THAILAND DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 98 THAILAND DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 99 THAILAND THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 100 THAILAND SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 101 PHILIPPINES SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 102 PHILIPPINES LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 103 PHILIPPINES SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 104 PHILIPPINES SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 105 PHILIPPINES DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 106 PHILIPPINES DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 107 PHILIPPINES THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 108 PHILIPPINES SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 109 REST OF ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

 

LIST OF FIGURES ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET

FIGURE 1 BELOW IS THE SCLERODERMA MAP DEFINING THE TYPES FIGURE 2 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: SEGMENTATION FIGURE 3 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: DATA TRIANGULATION FIGURE 4 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: DROC ANALYSIS FIGURE 5 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS FIGURE 6 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS FIGURE 7 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS FIGURE 8 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: DBMR MARKET POSITION GRID FIGURE 9 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET FIGURE 10 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: SEGMENTATION FIGURE 11 RISING CASES OF SCLERODERMA, INCREASING ACCESS TO MEDICAL INSURANCE IN THE U.S., INCREASING MERGER AND ACQUISITIONS IS EXPECTED TO DRIVE THE ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET IN THE FORECAST PERIOD 2019 TO 2026 FIGURE 12 SYSTEMIC SCLERODERMA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET IN 2019 & 2026 FIGURE 13 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: BY TYPE , 2018 FIGURE 14 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: BY TREATMENT TYPE , 2018 FIGURE 15 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: BY END USER, 2018 FIGURE 16 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: SNAPSHOT (2018) FIGURE 17 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018) FIGURE 18 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026) FIGURE 19 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026) FIGURE 20 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: BY TYPE (2019-2026) FIGURE 21 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: COMPANY SHARE 2018 (%)

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $3200.00
  • $2500.00
BUY NOW ADD TO CART